MA32797B1 - Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one - Google Patents

Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one

Info

Publication number
MA32797B1
MA32797B1 MA33846A MA33846A MA32797B1 MA 32797 B1 MA32797 B1 MA 32797B1 MA 33846 A MA33846 A MA 33846A MA 33846 A MA33846 A MA 33846A MA 32797 B1 MA32797 B1 MA 32797B1
Authority
MA
Morocco
Prior art keywords
propylimino
thiazolidin
benz
ylidene
tolyl
Prior art date
Application number
MA33846A
Other languages
Arabic (ar)
English (en)
Inventor
Nicholas Bonham
Stephan Buchmann
Alex Eberlin
Christoph Imboden
Raumer Markus Von
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40097688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32797(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA32797B1 publication Critical patent/MA32797B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES FORMES CRISTALLINES DE LA (R)-5[3-CHLORO-4-(2,3-DIHYDROXY-PROPOXY)- BENZ-[Z]-YLIDÈNE]-2-([Z]-PROPYLIMINO)-3-O-TOLYL-THIAZOLIDIN-4-ONE, DES PROCÉDÉS POUR LEUR PRÉPARATION, DES COMPOSITIONS PHARMACEUTIQUES CONTENANT LESDITES FORMES CRISTALLINES, ET LEUR UTILISATION COMME COMPOSÉS AMÉLIORANT LA FONCTION VASCULAIRE ET COMME AGENTS IMMUNOMODULATEURS, SOIT SEULS, SOIT EN ASSOCIATION AVEC D'AUTRES COMPOSÉS ACTIFS OU THÉRAPIES.
MA33846A 2008-10-20 2011-05-13 Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one MA32797B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0819182.7A GB0819182D0 (en) 2008-10-20 2008-10-20 Crystalline forms
PCT/IB2009/054592 WO2010046835A1 (fr) 2008-10-20 2009-10-19 Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl-thiazolidin-4-one

Publications (1)

Publication Number Publication Date
MA32797B1 true MA32797B1 (fr) 2011-11-01

Family

ID=40097688

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33846A MA32797B1 (fr) 2008-10-20 2011-05-13 Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one

Country Status (27)

Country Link
US (1) US9062014B2 (fr)
EP (1) EP2344465B1 (fr)
JP (1) JP5008777B2 (fr)
KR (1) KR101409597B1 (fr)
CN (1) CN102177144B (fr)
AR (1) AR073904A1 (fr)
AU (1) AU2009305980C1 (fr)
BR (1) BRPI0919673B1 (fr)
CA (1) CA2740313C (fr)
CL (1) CL2011000867A1 (fr)
CY (1) CY1116118T1 (fr)
DK (1) DK2344465T3 (fr)
ES (1) ES2534333T3 (fr)
GB (1) GB0819182D0 (fr)
HR (1) HRP20150391T1 (fr)
IL (1) IL212351A (fr)
MA (1) MA32797B1 (fr)
MX (1) MX2011003988A (fr)
MY (1) MY160703A (fr)
NZ (1) NZ592854A (fr)
PL (1) PL2344465T3 (fr)
PT (1) PT2344465E (fr)
RU (1) RU2519548C2 (fr)
SI (1) SI2344465T1 (fr)
TW (1) TWI462911B (fr)
WO (1) WO2010046835A1 (fr)
ZA (1) ZA201103691B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
USRE43728E1 (en) 2003-11-21 2012-10-09 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
TWI460166B (zh) * 2006-11-23 2014-11-11 Actelion Pharmaceuticals Ltd 製備２-亞胺基-四氫噻唑-４-酮衍生物之新穎方法
PL2278960T5 (pl) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1
JP6212485B2 (ja) * 2011-06-02 2017-10-11 キノイン・ゼー・エル・テー プロスタグランジンアミドの新規製造方法
SMT202000298T1 (it) * 2012-08-17 2020-07-08 Actelion Pharmaceuticals Ltd Processo per la produzione di (2z,5z)-5-(3-cloro-4((r)-2,3-diidrossipropossi) benziliden)-2-(propilimmino)-3-(o-tolil)tiazolidin-4-one e intermedio usato in detto processo
KR20200013086A (ko) 2014-12-11 2020-02-05 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
JP6691218B2 (ja) * 2015-12-25 2020-04-28 クリスタル ファーマテック カンパニー、リミテッドＣｒｙｓｔａｌ Ｐｈａｒｍａｔｅｃｈ Ｃｏ．， Ｌｔｄ． 選択的なｓ１ｐ１受容体アゴニストの新規な結晶形及びその製造方法
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
EP3684358A4 (fr) 2017-09-19 2021-01-13 Teva Pharmaceuticals International GmbH Nouveau polymorphe cristallin du ponesimod
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en) * 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
BR112022001138A2 (pt) 2019-07-22 2022-03-15 Actelion Pharmaceuticals Ltd Métodos de tratamento de esclerose múltipla
JP7749552B2 (ja) 2019-10-31 2025-10-06 イドルシア・ファーマシューティカルズ・リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
WO2021143414A1 (fr) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 Forme cristalline de ponesimod, son procédé de préparation et son utilisation
US20230123588A1 (en) 2020-03-06 2023-04-20 Actelion Pharmaceuticals Ltd Methods of slowing brain volume loss
EP4387960A1 (fr) 2021-08-17 2024-06-26 Teva Czech Industries s.r.o Polymorphes de ponésimod
WO2023061939A1 (fr) 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Méthodes de traitement de la sclérose en plaques
WO2023062511A1 (fr) 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Méthodes de traitement de la sclérose en plaques
US20230113378A1 (en) 2021-10-11 2023-04-13 Actelion Pharmaceuticals Ltd Methods Of Treating Multiple Sclerosis
CA3220684A1 (fr) 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Methodes de traitement de la sclerose en plaques
US20240261267A1 (en) 2021-11-05 2024-08-08 Vanda Pharmaceuticals Inc. Methods for treating multiple sclerosis
EP4212156A1 (fr) 2022-01-13 2023-07-19 Abivax Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un modulateur de récepteur de s1p
CA3220702A1 (fr) 2022-02-11 2023-08-17 Actelion Pharmaceuticals Ltd Methodes de ralentissement d'une augmentation du volume ventriculaire cerebral

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79793C2 (en) * 2002-07-10 2007-07-25 Applied Research Systems Azolidinone-vinyl fused-benzene derivatives
US7892354B2 (en) * 2003-10-06 2011-02-22 Solvias Ag Process for the parallel detection of crystalline forms of molecular solids
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
USRE43728E1 (en) * 2003-11-21 2012-10-09 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
TWI460166B (zh) 2006-11-23 2014-11-11 Actelion Pharmaceuticals Ltd 製備２-亞胺基-四氫噻唑-４-酮衍生物之新穎方法
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
PL2278960T5 (pl) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1

Also Published As

Publication number Publication date
HK1159624A1 (en) 2012-08-03
EP2344465B1 (fr) 2015-01-07
US20110196004A1 (en) 2011-08-11
AU2009305980A1 (en) 2010-04-29
MY160703A (en) 2017-03-15
EP2344465A1 (fr) 2011-07-20
IL212351A (en) 2015-09-24
AU2009305980C1 (en) 2015-01-22
CA2740313C (fr) 2016-09-27
TWI462911B (zh) 2014-12-01
RU2011119898A (ru) 2012-11-27
GB0819182D0 (en) 2008-11-26
CL2011000867A1 (es) 2011-09-23
ZA201103691B (en) 2015-12-23
CA2740313A1 (fr) 2010-04-29
KR101409597B1 (ko) 2014-06-20
DK2344465T3 (en) 2015-02-16
CY1116118T1 (el) 2017-02-08
MX2011003988A (es) 2011-05-10
BRPI0919673A2 (pt) 2020-09-15
NZ592854A (en) 2013-01-25
CN102177144A (zh) 2011-09-07
BRPI0919673B1 (pt) 2022-02-08
ES2534333T3 (es) 2015-04-21
WO2010046835A1 (fr) 2010-04-29
JP2012505873A (ja) 2012-03-08
SI2344465T1 (sl) 2015-04-30
KR20110071133A (ko) 2011-06-28
CN102177144B (zh) 2014-12-31
AR073904A1 (es) 2010-12-09
AU2009305980B2 (en) 2014-10-02
HRP20150391T1 (hr) 2015-05-22
IL212351A0 (en) 2011-06-30
US9062014B2 (en) 2015-06-23
PT2344465E (pt) 2015-04-23
TW201022220A (en) 2010-06-16
JP5008777B2 (ja) 2012-08-22
RU2519548C2 (ru) 2014-06-10
PL2344465T3 (pl) 2015-06-30

Similar Documents

Publication Publication Date Title
MA32797B1 (fr) Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
SMT201400142B (it) Composti di N-(1H-indazol-4-il) immidazo[1,2-A]piridin-3-carbossammide sostituita come inibitori di cfms
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
BRPI0820139A2 (pt) Composição antiperspirante ativa, e, processo de obtenção de uma composição antiperspirante ativa
EP2350054A4 (fr) Dérivés d'azétidine comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
CL2014000270A1 (es) Compuestos derivados de 3,5-difenil diazoles sustituidos, inhibidores de la agregacion de proteinas. (divisional de la solicitud n° 1369-2010).
UA97834C2 (ru) Производные сульфониламида для лечения анормального роста клеток
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201070853A1 (ru) Кристаллический (r)-2-(4-циклопропансульфонилфенил)-n-пиразин-2-ил-3-(тетрагидропиран-4-ил)пропионамид
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UY31688A1 (es) Plaguicidas
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
EP2130549A4 (fr) Préparation de fibrinogène solide
EP2373326A4 (fr) Formes cristallines de la génistéine
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
SE0800742L (sv) Vikttäcke
ECSP088740A (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos y su uso como antiinflamatorios
MX2010006636A (es) Uso de derivados de acido tetramico para controlar nematodos.
PT1901783E (pt) Ácido gentísico para estabilização de radiofármacos com 123-i
CO6341474A2 (es) Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su uso
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
EA201170721A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов рецептора хемокина
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина